AntagomiR-based treatment for T2D: MiRNA-1 decreases insulin sensitivity via down regulation of a regulator of insulin receptor, Caveolin-1, Genome-2-Bio-Medicine Discovery center (GBMD), 19/08/2014, 10.51 am